125 filings
Page 3 of 7
8-K
2iv16w35eh77m 51ke
20 Jan 23
Departure of Directors or Certain Officers
8:03am
8-K
rbh3cul6
18 Jan 23
Entry into a Material Definitive Agreement
4:28pm
8-K
7q1 j9v3g4aqa
17 Jan 23
180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom
8:00am
8-K
qpdo3ysj
12 Jan 23
Entry into a Material Definitive Agreement
5:00pm
8-K
gj80pjsqz44v 1e
5 Jan 23
Other Events
9:30am
8-K
h9zk3af3gyphhzafhim6
4 Jan 23
180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease
8:30am
8-K
i4z ezeiq7yj91lfk
29 Dec 22
Entry into a Material Definitive Agreement
4:30pm
8-K
z4eq9jij
29 Dec 22
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders
8:30am
8-K
ulaymigws ko7esn7
22 Dec 22
180 Life Sciences Corp. Announces $6 Million Registered Direct Offering
5:15pm
8-K
5pr00 esin5
16 Dec 22
180 Life Sciences Corp. Announces 1-FOR 20 Reverse Stock Split As Part of Nasdaq Compliance Plan
9:00am
8-K
1p6 7nc1o
30 Nov 22
Regulation FD Disclosure
5:00pm
8-K
u2n4xk99xd
15 Nov 22
Adalimumab Found To Be a Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease
4:15pm
8-K
u8z3wafp1ny urkf
4 Oct 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:30am
8-K
erd6a72 3smb
26 Sep 22
180 Life Sciences Issues Letter to Stockholders
8:30am
8-K
ixawo6gc
22 Aug 22
Regulation FD Disclosure
8:31am
8-K
jdaiskiq4ujt1
27 Jul 22
Regulation FD Disclosure
8:35am
8-K
7yj7wjs
19 Jul 22
180 Life Sciences Corp. Announces $6.5 Million Registered Direct Offering
4:11pm
8-K
9z8qafvh4mil3467
22 Jun 22
180 Life Sciences Corp. Issues Letter to Stockholders
4:15pm
8-K
ik31lqqcf2nqh9fg5
14 Jun 22
Departure of Directors or Certain Officers
4:15pm
8-K
p7h22j
26 May 22
Departure of Directors or Certain Officers
8:45pm